Plant Name: Nandina domestica
Taxonomic Information:
Plant ID: NPO28410
Plant Latin Name: Nandina domestica
Taxonomy Genus: Nandina
Taxonomy Family: Berberidaceae
Plant External Links:
NCBI TaxonomyDB:
41776
Plant-of-the-World-Online:
107544-1
Used in Medicines:
Unknown.
Geographical Distribution:
United States; South Africa
Example Image
Geographical Distribution
See the Plant Occurrence Worldwide with Latitude and Longitude Available
Collective Molecular Activities of the Plant
List of Human Proteins Collectively Targeted by the Plant
Click Gene ID to Access Activity Profile of Individual Target
| HTR7; ADRA1A; HTR2A; HTR1A; | |
| F3; LMNA; |
List of Human Cytochrome P450 Enzymes Affected by the Plant
Click Gene ID to Access Activity Profile of Individual Enzyme
| Cytochrome P450 Enzymes: | CYP2D6; |
|---|
Detailed Information of Target Proteins
| Protein Class | Gene ID | Protein Name | Uniprot ID | Target ChEMBL ID |
|---|---|---|---|---|
| Cytochrome P450 family 2 | CYP2D6 | Cytochrome P450 2D6 | P10635 | CHEMBL289 |
| Small molecule receptor (family A GPCR) | HTR7 | Serotonin 7 (5-HT7) receptor | P34969 | CHEMBL3155 |
| Small molecule receptor (family A GPCR) | ADRA1A | Alpha-1a adrenergic receptor | P35348 | CHEMBL229 |
| Small molecule receptor (family A GPCR) | HTR2A | Serotonin 2a (5-HT2a) receptor | P28223 | CHEMBL224 |
| Small molecule receptor (family A GPCR) | HTR1A | Serotonin 1a (5-HT1a) receptor | P08908 | CHEMBL214 |
| Unclassified | F3 | Coagulation factor III | P13726 | CHEMBL4081 |
| Unclassified | LMNA | Prelamin-A/C | P02545 | CHEMBL1293235 |
Enrichment of Gene Ontology of Target Proteins (Activity≤10μM)
Detailed Information of Enriched Gene Ontolgy
| GO Type | GO Category | Enriched GO Terms | p-Value | Adjusted p-Value | Enriched Genes |
|---|---|---|---|---|---|
| BP | Unclassified; | GO:0042310; vasoconstriction | 1.429E-10 | 3.112E-06 | ADRA1A, HTR1A, HTR2A, HTR7 |
| MF | GO:0005488; binding | GO:0051378; serotonin binding | 4.803E-09 | 2.092E-05 | HTR1A, HTR2A, HTR7 |
| BP | GO:0032501; multicellular organismal process | GO:0097746; regulation of blood vessel diameter | 5.578E-08 | 1.164E-04 | ADRA1A, HTR1A, HTR2A, HTR7 |
| BP | GO:0009987; cellular process | GO:0007210; serotonin receptor signaling pathway | 5.879E-08 | 1.164E-04 | HTR1A, HTR2A, HTR7 |
| MF | GO:0060089; molecular transducer activity | GO:0004993; G-protein coupled serotonin receptor activity | 5.879E-08 | 1.164E-04 | HTR1A, HTR2A, HTR7 |
| BP | GO:0032501; multicellular organismal process | GO:0006939; smooth muscle contraction | 5.005E-07 | 6.411E-04 | ADRA1A, HTR2A, HTR7 |
| BP | GO:0009987; cellular process | GO:0007198; adenylate cyclase-inhibiting serotonin receptor signaling pathway | 6.752E-07 | 7.738E-04 | HTR1A, HTR7 |
| CC | GO:0016020; membrane | GO:0005901; caveola | 2.764E-04 | 1.281E-01 | ADRA1A, HTR2A |
| CC | GO:0044425; membrane part | GO:0005887; integral component of plasma membrane | 8.249E-04 | 2.631E-01 | ADRA1A, HTR1A, HTR2A, HTR7 |
| CC | GO:0016020; membrane | GO:0016020; membrane | 1.711E-03 | 4.435E-01 | ADRA1A, CYP2D6, F3, HTR1A, HTR2A, HTR7, LMNA |
| CC | GO:0016020; membrane | GO:0098857; membrane microdomain | 4.640E-03 | 7.053E-01 | ADRA1A, HTR2A |
Enriched KEGG Pathways of Target Proteins (Activity≤10μM)
Top 10 KEGG Pathways (ordered by adjusted p-value)
Detailed Information of Enriched KEGG Pathways
| Pathway Category Top Level | Pathway Category Second Level | Pathway ID | Pathway Name | p-Value | Adjusted p-Value | Enriched Genes |
|---|---|---|---|---|---|---|
| 09150 Organismal Systems | 09156 Nervous system | hsa04726 | Serotonergic synapse | 3.220E-08 | 6.761E-07 | HTR7, CYP2D6, HTR1A, HTR2A |
| 09130 Environmental Information Processing | 09133 Signaling molecules and interaction | hsa04080 | Neuroactive ligand-receptor interaction | 1.220E-06 | 1.281E-05 | HTR7, HTR1A, HTR2A, ADRA1A |
| 09130 Environmental Information Processing | 09132 Signal transduction | hsa04020 | Calcium signaling pathway | 2.444E-05 | 1.711E-04 | HTR7, HTR2A, ADRA1A |
| 09100 Metabolism | 09111 Xenobiotics biodegradation and metabolism | hsa00982 | Drug metabolism - cytochrome P450 | 2.391E-02 | 5.224E-02 | CYP2D6 |
| 09100 Metabolism | 09111 Xenobiotics biodegradation and metabolism | hsa00980 | Metabolism of xenobiotics by cytochrome P450 | 2.528E-02 | 5.224E-02 | CYP2D6 |
| 09160 Human Diseases | 09165 Cardiovascular diseases | hsa05412 | Arrhythmogenic right ventricular cardiomyopathy (ARVC) | 2.562E-02 | 5.224E-02 | LMNA |
| 09150 Organismal Systems | 09157 Sensory system | hsa04742 | Taste transduction | 2.870E-02 | 5.224E-02 | HTR1A |
| 09150 Organismal Systems | 09151 Immune system | hsa04610 | Complement and coagulation cascades | 2.733E-02 | 5.224E-02 | F3 |
| 09160 Human Diseases | 09166 Endocrine and metabolic diseases | hsa04933 | AGE-RAGE signaling pathway in diabetic complications | 3.482E-02 | 5.224E-02 | F3 |
| 09150 Organismal Systems | 09154 Digestive system | hsa04970 | Salivary secretion | 3.074E-02 | 5.224E-02 | ADRA1A |
Human Diseases Associated with the Target Proteins of the Plant
Detailed Information of Human Diseases
| ICD10 Disease Category | Disease Name | ICD10 Code | Associated Disease Targets (Association Ref: TTD database) |
|---|---|---|---|
| NA: NA | Addiction | NA | HTR2A; |
| J00-J99: Diseases of the respiratory system | Adult respiratory distress syndrome | J80 | F3; |
| R00-R99: Symptoms, signs and abnormal clinical and laboratory findings, not elsewhere classified | Spasm | R25.2 | HTR1A; |
| NA: NA | Social phobia | NA | HTR1A; |
| A00-B99: Certain infectious and parasitic diseases | Malaria | B54 | CYP2D6; |
| NA: NA | Episode | NA | HTR1A; |
| E00-E89: Endocrine, nutritional and metabolic diseases | Erythropoietic porphyria | E80.0 | HTR2A; |
| N00-N99: Diseases of the genitourinary system | Prostate hyperplasia | N40 | ADRA1A; |
| C00-D49: Neoplasms | Prostate cancer | C61 | ADRA1A; |
| N00-N99: Diseases of the genitourinary system | Prostate disease | N42.9 | ADRA1A; |
| F01-F99: Mental, Behavioral and Neurodevelopmental disorders | Alcohol use disorders | F10.2 | HTR2A; |
| F01-F99: Mental, Behavioral and Neurodevelopmental disorders | Psychotic disorders | F20-F29 | HTR1A; |
| F01-F99: Mental, Behavioral and Neurodevelopmental disorders | Psychiatric disorder | F01-F99 | HTR2A; HTR1A; |
| I00-I99: Diseases of the circulatory system | Coronary artery disease | I20-I25 | HTR1A; |
| E00-E89: Endocrine, nutritional and metabolic diseases | Eating disorder | E66, F50, I10-I16, I50 | HTR1A; |
| G00-G99: Diseases of the nervous system G00-G99 | Alzheimer disease | G30 | HTR1A; |
| NA: NA | Anxiety disorders | NA | HTR1A; |
| F01-F99: Mental, Behavioral and Neurodevelopmental disorders | Mood disorder | F30-F39 | HTR2A; HTR1A; |
| G00-G99: Diseases of the nervous system G00-G99 | Pain | G64, G90.0, R52, G89 | ADRA1A; HTR1A; |
| C00-D49: Neoplasms | Pancreatic cancer | C25 | F3; |
| K00-K95: Diseases of the digestive system | Pancreatitis | K85, K86.0K86.1 | HTR2A; |
| G00-G99: Diseases of the nervous system G00-G99 | Parkinson's disease | G20 | HTR1A; |
| F01-F99: Mental, Behavioral and Neurodevelopmental disorders | Hypoactive sexual desire disorder | F52.0 | HTR1A; |
| F01-F99: Mental, Behavioral and Neurodevelopmental disorders | Post-traumatic stress disorder | F43.1 | ADRA1A; |
| F01-F99: Mental, Behavioral and Neurodevelopmental disorders | Premature ejaculation | F52.4 | HTR1A; |
| N00-N99: Diseases of the genitourinary system | Stress urinary incontinence | N39.3 | ADRA1A; |
| M00-M99: Diseases of the musculoskeletal system and connective tissue | Fibromyalgia | M79.7 | HTR2A; |
| F01-F99: Mental, Behavioral and Neurodevelopmental disorders | Female sexual dysfunction | F52 | ADRA1A; HTR1A; |
| G00-G99: Diseases of the nervous system G00-G99 | Migraine | G43 | CYP2D6; HTR2A; HTR1A; |
| NA: NA | Peripheral sensory neuropathies | NA | HTR1A; |
| I00-I99: Diseases of the circulatory system | Hemorrhoids | I84 | HTR2A; |
| F01-F99: Mental, Behavioral and Neurodevelopmental disorders | Major depressive disorder | F32, F33, M32 | HTR7; ADRA1A; HTR1A; |
| G00-G99: Diseases of the nervous system G00-G99 | Lateral sclerosis | G12.2 | HTR1A; |
| NA: NA | Cervical dystonia | NA | HTR1A; |
| G00-G99: Diseases of the nervous system G00-G99 | Central nervous system disease | G00-G99 | HTR2A; |
| F01-F99: Mental, Behavioral and Neurodevelopmental disorders | Cognitive disorders | F01-F07, F04, F05, R41.3 | ADRA1A; HTR1A; |
| H00-H59: Diseases of the eye and adnexa | Glaucoma | H40-H42 | ADRA1A; HTR2A; |
| F01-F99: Mental, Behavioral and Neurodevelopmental disorders | Insomnia | F51.0, G47.0 | CYP2D6; |
| F01-F99: Mental, Behavioral and Neurodevelopmental disorders | Generalized anxiety disorder | F32, F40-F42, F41.1 | HTR1A; |
| I00-I99: Diseases of the circulatory system | Bleeding | I74, I80-I82 | F3; |
| I00-I99: Diseases of the circulatory system | Hypertension | I10-I16 | ADRA1A; HTR1A; |
| N00-N99: Diseases of the genitourinary system | Benign prostatic hyperplasia | N40 | ADRA1A; |
| E00-E89: Endocrine, nutritional and metabolic diseases | Diabetes | E23.2, N25.1 | HTR2A; |
| F01-F99: Mental, Behavioral and Neurodevelopmental disorders | Anxiety disorder | F32, F40-F42 | HTR2A; HTR1A; |
| I00-I99: Diseases of the circulatory system | Cardiovascular disorder | I00-I99 | HTR2A; |
| NA: NA | Schizoaffective disorder | NA | HTR1A; |
| F01-F99: Mental, Behavioral and Neurodevelopmental disorders | Depression | F30-F39 | HTR2A; HTR1A; |
| NA: NA | Bulimia nervosa | NA | HTR1A; |
| F01-F99: Mental, Behavioral and Neurodevelopmental disorders | Schizophrenia | F20 | HTR7; HTR2A; HTR1A; |
| F01-F99: Mental, Behavioral and Neurodevelopmental disorders | Sleep disorders | F51, G47 | HTR7; HTR2A; |
| F01-F99: Mental, Behavioral and Neurodevelopmental disorders | Severe mood disorders | F30-F39 | HTR1A; |
| F01-F99: Mental, Behavioral and Neurodevelopmental disorders | Sleep maintenance insomnia | F51.0, G47.0 | HTR2A; |
| N00-N99: Diseases of the genitourinary system | Urinary incontinence | N39.3, N39.4, R32 | ADRA1A; HTR1A; |
>> Profiles of ingredients and activity landscape
>> Targets derived from weak experimental activities
